Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT03800836 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03800836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03800836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
February 13, 2018
Completion date
March 16, 2022
Enrollment
139 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer